Suppr超能文献

从传统中药中鉴定出毛药忍冬苷C作为一种新型ADAM10增强剂。

Identification of Phlogacantholide C as a Novel ADAM10 Enhancer from Traditional Chinese Medicinal Plants.

作者信息

Meineck Myriam, Schuck Florian, Abdelfatah Sara, Efferth Thomas, Endres Kristina

机构信息

Clinic of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.

Institute of Pharmacy, Johannes Gutenberg-University Mainz, 55099 Mainz, Germany.

出版信息

Medicines (Basel). 2016 Dec 5;3(4):30. doi: 10.3390/medicines3040030.

Abstract

Alzheimer's disease is one of the most prevalent dementias in the elderly population with increasing numbers of patients. One pivotal hallmark of this disorder is the deposition of protein aggregates stemming from neurotoxic amyloid-beta peptides. Synthesis of those peptides has been efficiently prevented in AD model mice by activation of an enzyme called alpha-secretase. Therefore, drugs with the capability to increase the expression of this enzyme, named ADAM10, have been suggested as a valuable therapeutic medication. We investigated 69 substances from a drug library derived from traditional Chinese medicine by luciferase reporter assay in human neuronal cells for their potential to selectively induce alpha-secretase expression. Western blot analysis was used to confirm results on the protein level. Ten of the 69 investigated compounds led to induction of ADAM10 transcriptional activity while BACE-1 (beta-site APP cleaving enzyme 1) and APP (amyloid precursor protein) expression were not induced. Two of them-Norkurarinol and Phlogacantholide C-showed substantial elevation of ADAM10 protein levels and Phlogacantholide C also increased secretion of the ADAM10-derived cleavage product APPs-alpha. Phlogacantholide C represents a novel ADAM10 gene expression enhancer from traditional Chinese medicinal herbs that may lay the groundwork for evolving potential novel therapeutics in Alzheimer's disease.

摘要

阿尔茨海默病是老年人群中最常见的痴呆症之一,患者数量不断增加。这种疾病的一个关键特征是由神经毒性淀粉样β肽产生的蛋白质聚集体的沉积。在AD模型小鼠中,通过激活一种名为α-分泌酶的酶,这些肽的合成已被有效阻止。因此,具有增加这种名为ADAM10的酶表达能力的药物被认为是一种有价值的治疗药物。我们通过荧光素酶报告基因检测法,在人神经细胞中研究了来自中药的69种物质的药物库,以检测它们选择性诱导α-分泌酶表达的潜力。蛋白质印迹分析用于在蛋白质水平上确认结果。在69种被研究的化合物中,有10种导致了ADAM10转录活性的诱导,而β-位点APP裂解酶1(BACE-1)和淀粉样前体蛋白(APP)的表达未被诱导。其中两种化合物——降二氢卡拉任醇和黄腺香茶菜甲素C——显示出ADAM10蛋白水平的显著升高,黄腺香茶菜甲素C还增加了ADAM10衍生的裂解产物APPs-α的分泌。黄腺香茶菜甲素C是一种来自传统中草药的新型ADAM10基因表达增强剂,可能为开发阿尔茨海默病潜在的新型治疗方法奠定基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e21/5456242/762a88633dba/medicines-03-00030-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验